On May 25, 2021, Emboline, Inc., a privately-held medical device company focused on reducing stroke and other damage caused by embolic debris released during transcatheter heart procedures, announced the closing of its Series D funding of over $55 million. Wilson Sonsini Goodrich & Rosati represented Emboline in the transaction.

This funding was led by new investors Matrix Capital Management and an undisclosed strategic investor, with additional participation by existing investors, including SV Tech, ShangBay Capital, and Global Assets Investment. This investment will support a planned U.S.-based pivotal trial for FDA approval as well as investigational studies for new indications, and manufacturing and commercial operations for the Emboliner™.

The Wilson Sonsini team that represented Emboline in the transaction included Elton Satusky, Eric Hsu, and Kathy Jordan.

For more information, please see Emboline's press release.